ArticleUnited European gastroenterology journal2019

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Claire Liefferinckx et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.